Negative Pressure Applied by the Equinox MPD for Severe Open Angle Glaucoma

NCT04632329 | Completed FDA Device

• 1 other identifier: CP-022
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 3

Brief Summary

This is a prospective, non-significant risk, controlled, randomized, multi-center, masked, feasibility study to evaluate the safety and IOP-lowering effectiveness of negative pressure application (via the Mercury MPD) for lowering and titrating intraocular pressure (IOP) in severe open-angle glaucoma (OAG) patients. The study will be conducted at approximately three investigational sites in the United States. Between 60 and 100 subjects will be randomized to treatment. Treatment eyes will be administered two levels of negative pressure, calculated based on 50% and 75% of baseline IOP (as measured by pneumatonometry). One eye of each eligible subject will be randomized to receive negative pressure application with the MPD device; the contralateral eye will be used as a control and will be examined but will not undergo application of negative pressure. Subjects will be treated at each of the negative pressure levels for one hour. All study procedures will be conducted at one visit, and the subject will exit the study at the conclusion of the visit.

Conditions

Glaucoma, Open-Angle

Outcome Measures

Primary Outcomes (2)

• IOP* reduction of ≥ 20% with 50% Negative Pressure for the treatment group vs. the control group

  Feasibility to lower intraocular pressure inside the eye in 1 treatment session (1-day). Not a measure of glaucoma progression health outcome. Difference in IOP as measured via pneumatonometry with Excursion goggles worn immediately before vs. during application of negative pressure.

  Day 1

• Mean IOP*reduction with 50% Negative Pressure for the treatment group vs. the control group

  Feasibility to lower intraocular pressure inside the eye in 1 treatment session (1-day). Not a measure of glaucoma progression health outcome. \*Difference in IOP as measured via pneumatonometry with Excursion goggles worn immediately before vs. during application of negative pressure

  Day 1

Secondary Outcomes (2)

• IOP* reduction of ≥ 25% with 75% Negative Pressure for the treatment group vs. the control group

  Day 1

• Mean IOP*reduction with 75% Negative Pressure for the treatment group vs. the control group

  Day 1

Other Outcomes (3)

• Adverse Biomicroscopic Slit Lamp Findings

  Day 1

• Rate of ocular/periocular adverse events (% by adverse event)

  Day 1

• Corrected Distance Visual Acuity

  Day 1

Study Arms (2)

Negative Pressure

EXPERIMENTAL

Device: Negative Pressure Treatment via the Mercury Multi-Pressure Dial

Control Eye

NO INTERVENTION

Interventions

Negative Pressure Treatment via the Mercury Multi-Pressure Dial DEVICE

Negative Pressure Treatment via the Mercury Multi-Pressure Dial

Negative Pressure

Eligibility Criteria

• Age: 22 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female subjects ≥ 22 years of age at the time of signing the informed consent
• Subjects willing to sign the informed consent and capable of committing to the study assessments
• Subjects with orbital anatomy that permits a proper seal in both eyes when goggles are placed over eyes and can obtain IOP measurements with Excursion goggles in place
• Subjects with a diagnosis of severe open-angle glaucoma (OAG definition is inclusive of primary open angle glaucoma, normal tension glaucoma, pseudoexfoliative glaucoma, and pigmentary glaucoma) in at least one eye, defined by glaucomatous optic disc or RNFL abnormalities AND visual field abnormalities in both hemifields and/or loss within 5 degrees of fixation in at least one hemifield as tested with standard automated perimetry (the diagnosis of the contralateral eye may include suspected OAG\< as well as mild/moderate/severe OAG)
• Subjects with treatment regimens including current ocular hypotensive medications, prior non-incisional surgical procedures (e.g. MIGS and SLT), or any combination of the two
• Subjects who are literate, able to speak English or Spanish, and able to understand and follow study instructions

You may not qualify if:

• Subjects with a history of allergy to primary study device material (i.e., silicone and latex)
• Subjects with a history of any ocular disorder or condition (e.g., corneal transplant) in either eye that would likely interfere with the interpretation of the study results or compromise subject safety
• Subjects with a history of retinal tear/detachment, wet macular degeneration, diabetic macular edema, or proliferative diabetic retinopathy
• Subjects with active conjunctival chemosis or anterior uveitis
• Subjects with a Van Herick grade of 2 or less.
• Subjects with a history of prior incisional filtering (i.e. trabeculectomy) or tube/shunt glaucoma surgery in either eye
• Subjects with best corrected visual acuity of 20/200 or worse in either eye due to glaucoma
• Subjects who do not wish to or cannot comply with study procedures

Sponsors & Collaborators

• Equinox: lead

Study Sites (3)

Illinois College of Optometry

Chicago, Illinois, 60616, United States

Location

Vance Thompson Vision

Sioux Falls, South Dakota, 57108, United States

Location

R and R Eye Research, LLC

San Antonio, Texas, 78229, United States

Location

MeSH Terms

Conditions

Glaucoma, Open-Angle

Condition Hierarchy (Ancestors)

Glaucoma; Ocular Hypertension; Eye Diseases

Study Officials

• Nate Radliffe, MD

  New York Eye Surgery Center

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: CARE PROVIDER, OUTCOMES ASSESSOR
• Purpose: DEVICE FEASIBILITY
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 31, 2020
• First Posted: November 17, 2020
• Study Start: October 28, 2020
• Primary Completion: August 19, 2021
• Study Completion: August 19, 2021
• Last Updated: November 10, 2022

Record last verified: 2022-11

Locations

US (3)